Valneva

About

Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases.

Saint-herblain,Pays de la Loire,France
501 - 1000
http://www.valneva.com

Highlights

Stock Symbol

nasdaq:VALN

Total Funding Amount

€486.80M $212.60M £20M

Details

Last Funding Type: Post-IPO Equity
Last Funding Money Raised: €90.50M
Industries: Biotechnology,Health Care,Medical
Founded date: Jan 1, 2013
Number Of Employee: 501 - 1000
Operating Status: Active
Stock Symbol: nasdaq:VALN
Legal Name: Valneva SE

Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The comapany focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical needs. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus, and COVID-19.

It was founded in 2013 and is headquartered in Saint-herblain, France.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

13

€486.80M $212.60M £20M

Valneva has raised a total of €486.80M $212.60M £20M in funding over 2 rounds. Their latest funding was raised on Sep 30, 2022 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Sep 30, 2022	Post-IPO Equity	€102.90M	2	—	—	Detail
Jun 20, 2022	Post-IPO Equity	€90.50M	1	Pfizer	—	Detail
Apr 26, 2022	Post-IPO Debt	$20M	2	Deepfield OrbiMed	—	Detail
Feb 21, 2022	Grant	£20M	1	Scottish Enterprise	—	Detail
Nov 1, 2021	Post-IPO Equity	€88M	—	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

4

6

Valneva is funded by 6 investors. Pfizer and Deepfield are the most recent investors.

Investor Name	Lead Investor	Funding Round
Pfizer	Yes	Post-IPO Equity
Deepfield	Yes	Post-IPO Debt
OrbiMed	Yes	Post-IPO Debt
Scottish Enterprise	Yes	Grant
Bpifrance	—	Post-IPO Equity
Deep Track Capital	—	Post-IPO Equity